Navigation Links
Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
Date:12/9/2008

itional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. This press release

and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharm.com.


    [ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to Alexion on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2008 and in Alexion's other filings with the Securities and Exchange Commission. Alexion does not intend to update any of thes
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
2. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
3. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
9. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
10. NIST studies how new helium ion microscope measures up
11. SpectraCell Laboratories Now Measures Vitamin C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
(Date:10/20/2014)... 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... Q3 orders to $5.8 million and provides a good start to ... North America and one in the ... projects at record levels," said Peter Bruijns , President & ... end of Q3 than they have been for any complete year ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... has often been called "a game of inches," but biology ... a few nanometers can determine the fate of a cell ... cancerous. Scientists with the U.S. Department of Energy (DOE),s Lawrence ... better way to study the impact of spatial patterns on ...
... Calif., Nov. 1, 2011 Epitomics, Inc., a ... has received a Notice of Allowance from the ... Method for Identifying Differentially Expressed Proteins (application 10/705,109). ... differentially expressed proteins in cell samples using libraries ...
... DIEGO, Nov. 1, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... will present at the 20th Annual Credit Suisse Healthcare ... Time (7:00 AM Pacific Time). (Logo:   ... the presentation will be accessible on the Investors page ...
Cached Biology Technology:Berkeley Lab scientists develop new tool for the study of spatial patterns in living cells 2Berkeley Lab scientists develop new tool for the study of spatial patterns in living cells 3
(Date:10/15/2014)... assess the pandemic risk from strains of influenza virus ... allow ourselves to become complacent that the most substantial ... scientists. , Influenza pandemics arise when a new virus ... widespread immunity – spreads in the human population. There ... years, the worst of which – the 1918 Spanish ...
(Date:10/15/2014)... to an unexpected extent. The outbreak does not follow ... shows a new disease dynamic in regions, where it ... German National Academy of Sciences Leopoldina, acatech – the ... of the German Academies of Sciences and Humanities have ... In the statement the academies call for the following ...
(Date:10/15/2014)... be awarded the 44th Rosenstiel Award for Distinguished Work ... research exploring the mechanisms of genomic instability and its ... is the second alumnus to win the Rosenstiel Award; ... 2003. , Alt is the Charles A. Janeway Professor ... School and an investigator at the Howard Hughes Medical ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... Scientists from Hungary, Germany and the U.K. have discovered that ... the active ingredient in marijuana (THC), but these play ... on "endocannabinoids" just published online in, and scheduled for the ... could lead to new drugs that treat skin conditions ranging ...
... Fla. -- A Florida State University faculty member ... class of cancer-killing drugs is attracting worldwide attention ... assistant professor of chemical and biomedical engineering at ... Engineering, is using high-powered computers to determine how ...
... University have found that quantum dot nanoparticles can penetrate ... into potential workplace concerns for healthcare workers or individuals ... research on potential biomedical applications of the tiny nanoparticles. ... different sizes, shapes and surface coatings do not penetrate ...
Cached Biology News:FSU researcher using computers to hone cancer-fighting strategies 2Study shows quantum dots can penetrate skin through minor abrasions 2
... Biosearch Technologies has been at the ... accelerate the discovery and application of ... FRET probes and primers or 100 ... applications, Biosearch can meet your most ...
Cultrex 3D Culture Matrix Rat Collagen I....
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
Cultrex 3D Culture Matrix Laminin I....
Biology Products: